Results 11 to 20 of about 3,081 (193)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL [PDF]

International Journal of Molecular Sciences, 2019
B-cell receptor (BCR) signaling and tumor–microenvironment crosstalk both drive chronic lymphocytic leukemia (CLL) pathogenesis. Within the microenvironment, tumor cells shape the T-cell compartment, which in turn supports tumor growth and survival. Targeting BCR signaling using Bruton tyrosine kinase inhibitors (BTKi) has become a highly successful ...
Mhibik, Maissa, Wiestner, Adrian, Sun, Clare   +2 more
openaire   +3 more sources

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence [PDF]

Journal of Translational Medicine, 2021
Background The development of Bruton’s tyrosine kinase inhibitors (BTKi) for the treatment of chronic lymphocytic leukaemia (CLL) has provided a highly effective and relatively non-toxic alternative to conventional chemotherapy.
Joanne E. Davis, Chia Sharpe, Kylie Mason, Constantine S. Tam, Rachel M. Koldej, David S. Ritchie   +5 more
doaj   +2 more sources

Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis [PDF]

Frontiers in Pharmacology
We conducted this first systematic review and meta-analysis to assess the competitive advantage of 2nd-generation Bruton tyrosine kinase inhibitors (BTKi) compared to 1st-generation BTKi in chronic lymphocytic leukemia (CLL).
Liyuan Ke, Su Li, Danxue Huang, Yan Wang
doaj   +2 more sources

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial [PDF]

Haematologica
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BTKi,
Nirav N. Shah, Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Z inzani, Alvaro J. Alencar, Paolo Ghia, Nicole Lamanna, Marc S. Hoffmann, Manish R. Patel, Ian Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Maranda, Bita Fakhri, Won Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Donald E. Tsai, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Jennifer R. Brown   +34 more
doaj   +2 more sources

Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting [PDF]

Journal of Hematology & Oncology
Although covalent and non-covalent Bruton tyrosine kinase inhibitors (BTKi) have extended clinical benefit to relapsed/refractory (R/R) and BTKi-resistant chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), there remains an unmet need for ...
Pritika Sharma, Heng Jiang, Delong Liu
doaj   +2 more sources

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database

Cardio-Oncology
Background First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of ...
Srilakshmi Vallabhaneni, Srinath Adusumalli, Jingyi Wu, Peter W. Groeneveld, James Gerson, Rupal P. O’Quinn   +5 more
exaly   +2 more sources

Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL-2 Inhibitors. [PDF]

Cancer Med
ABSTRACT Background Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized. Methods We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing ...
Schulze FJ, Shumilov E, Behringer A, Kerkhoff A, Eckhardt M, Bätker S, Maulhardt M, Lenz G, Pohlmann A.   +8 more
europepmc   +2 more sources

Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell-surface CXCR4 as a synergistic target for combinatorial therapy. [PDF]

Hemasphere
HemaSphere, Volume 10, Issue 9, September 2026.
Mladonicka Pavlasova G, Sandova V, Ondrisova L, Seda V, Pavelkova P, Filip D, Hlavac K, Vecera J, Pospisilova S, Panovska A, Fernandes SM, Doubek M, Brown JR, Mraz M.   +13 more
europepmc   +2 more sources

Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study. [PDF]

Hematol Oncol
ABSTRACT Multiple targeted agents are available for first‐line treatment of chronic lymphocytic leukemia (CLL), yet the absence of mature head‐to‐head comparisons makes treatment selection challenging. The prospective, multicenter FIRST‐CLL study evaluated real‐world treatment allocation, and the contribution of biological, clinical, logistical and ...
Perutelli F, Arata M, Pasquale R, Pepe S, Nicolosi M, Deodato M, Piras I, Fioribello E, Bosi A, Moia R, Ferrario A, Schirru M, Boccellato E, Bullo M, Gottardi D, Foglietta M, Galitzia A, Coscia M, Gaidano G, Merli M, Salvetti C, Murru R, Frustaci AM, Freilone R, Olivieri J, Mauro FR, Bruno B, Vitale C.   +27 more
europepmc   +2 more sources

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

J Cell Mol Med
ABSTRACT Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment‐naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta‐analysis was intended to evaluate their efficacy, addressing critical gaps
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc   +2 more sources